Patent & IP news for April 12, 2017

Patent Litigations

USPTO Weekly Stats


Patent & IP Blogs

post image Time to celebrate, debate and have fun! Register for Fordham IP conference's 25th anniversary from

Time to get on-board to celebrate Fordham IP Conference's
25th Anniversary
The IPKat has been a long supporter and contributor to the phenomenal Fordham IP Conference, with many of our team speaking at or ...

Share via E–mail | Twitter | Facebook

post image Never Too Late: If you missed the IPKat last week! from

Been away and want to catch up on last week's IP news? No problem! As always, the IPKat is here to bring you a quick summary -- the 142nd edition of Never Too Late.
Conference ...

Share via E–mail | Twitter | Facebook

post image Author of Wall Street Charging Bull is raging over Fearless Girl, but does he have a valid moral right claim? from

Fearless GirlReaders will be aware that last month a sculpture by Kristen Visbal, entitled Fearless Girl, was unveiled in Manhattan's Financial District as an advertisement for an index fund which comprises gender diverse ...

Share via E–mail | Twitter | Facebook

post image Launch Event: Advancing women in tech, law and policy, ChIPs comes to London on 27 April 2017 from

Come to the UK Supreme Court for the ChIPs
launch event
Those who know the AmeriKat know she is an obsessive Harvard Business Review reader, so much so she is known to leave highlighted copies ...

Share via E–mail | Twitter | Facebook

post image Commission Roadmap: No Directive on SEPs (for now) from

It has been a busy couple of weeks for standard essential patents (SEPs).  Last week, we had the Unwired Plant v Huawei decision on FRAND (see post by the Amerikat here), and now we have ...

Share via E–mail | Twitter | Facebook

Attorney Fees for Resisting Motion to Compel Not Recoverable from

The court denied without prejudice a third party's motion to shift cost of discovery to plaintiff after the court granted plaintiff's motion to compel a third party to produce documents regarding five of ...

Share via E–mail | Twitter | Facebook

Generics Successful at Invalidating Novartis Gilenya Patent from

Novartis v. Torrent Pharma (Fed. Cir. 2017) At the conclusion of its Inter Partes Review (IPR) Trial, the Patent Trial & Appeal Board (PTAB) found all claims of Novartis U.S. Patent No. 8,324,283 ...

Share via E–mail | Twitter | Facebook

Novartis loses IPR appeal at CAFC in Torrent case from

This is an appeal from the Final Written Decision of
the United States Patent and Trademark Office, Patent
Trial and Appeal Board (Board) in two consolidated inter
partes review (IPR) proceedings of U.S. Patent ...

Share via E–mail | Twitter | Facebook

Some content © 2007–2017 RPX Corporation.
Terms of Service & Privacy Policy
For DMCA requests contact